Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies

English version České info

Human Cytomegalovirus (HCMV) is a double stranded DNA, enveloped virus infecting >60% of the population worldwide. Typically asymptomatic in healthy adults, HCMV infection causes morbidity and mortality in immunocompromised patients and is the most common viral cause of birth defects in industrialized countries. Despite more than 30 years of research, however, no vaccine against HCMV is available. HCMV utilizes two distinct glycoprotein complexes, gH/gL/gO and gH/gL/UL128/UL130/UL131A (Pentamer), to enter fibroblast and endothelial/epithelial cells, respectively and both are neutralizing antibodies targets. We used orthogonal techniques to study the interaction between gH/gL/gO or Pentamer and a panel of naturally occurring human neutralizing antibodies. The results of this analysis identify three neutralizing epitopes in gH, which are conserved in both glycoproteins complexes, and a different subset of five neutralizing sites in the UL128/Ul130/Ul131A (ULs) portion of the Pentamer. Moreover, EM analysis defines two distinct surfaces targeted by neutralizing antibodies on the ULs suggesting different neutralization mechanisms. Our results reveal regions of the gH/gL/gO and Pentamer complexes important for eliciting strong neutralizing responses in humans and for function in viral entry. Together our data will guide the development of therapeutic monoclonal antibodies and vaccines against HCMV.

Vyšlo v časopise: Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies. PLoS Pathog 11(10): e32767. doi:10.1371/journal.ppat.1005230
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1005230

Souhrn

Zdroje

1. Ho M (1990) Epidemiology of cytomegalovirus infections. Rev Infect Dis 12 Suppl 7: S701–710.

2. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE (1992) Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 166 : 1223–1227. 1358986

3. Kuppermann BD, Petty JG, Richman DD, Mathews WC, Fullerton SC, et al. (1993) Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 115 : 575–582. 8098183

4. Kotton CN (2010) Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 6 : 711–721. doi: 10.1038/nrneph.2010.141 20978468

5. Dasari V, Smith C, Khanna R (2013) Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases. Expert Rev Vaccines 12 : 661–676. doi: 10.1586/erv.13.46 23750795

6. Britt W (2008) Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 325 : 417–470. 18637519

7. Revello MG, Gerna G (2002) Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15 : 680–715. 12364375

8. Dollard SC, Grosse SD, Ross DS (2007) New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17 : 355–363. 17542052

9. Stratton KR, Durch JS, Lawrence RS (2000) Vaccines for the 21st Century: A Tool for Decisionmaking. National Academies Press, Washington, DC Institute of Medicine.

10. Adler SP (2008) Human CMV vaccine trials: what if CMV caused a rash? J Clin Virol 41 : 231–236. 18096431

11. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R, et al. (2004) Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39 : 233–239. 15307033

12. Sung H, Schleiss MR (2010) Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 9 : 1303–1314. doi: 10.1586/erv.10.125 21087108

13. Schleiss MR, McVoy MA (2010) Guinea Pig Cytomegalovirus (GPCMV): A Model for the Study of the Prevention and Treatment of Maternal-Fetal Transmission. Future Virol 5 : 207–217. 23308078

14. Pepperl-Klindworth S, Besold K, Frankenberg N, Farkas M, Kuball J, et al. (2006) Cytomegalovirus interleukin-10 expression in infected cells does not impair MHC class I restricted peptide presentation on bystanding antigen-presenting cells. Viral Immunol 19 : 92–101. 16553554

15. Sinzger C (2008) Entry route of HCMV into endothelial cells. J Clin Virol 41 : 174–179. doi: 10.1016/j.jcv.2007.12.002 18203656

16. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, et al. (2006) Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313 : 217–220. 16840698

17. Backovic M, Longnecker R, Jardetzky TS (2009) Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci U S A 106 : 2880–2885. doi: 10.1073/pnas.0810530106 19196955

18. Wang D, Shenk T (2005) Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 79 : 10330–10338. 16051825

19. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC (2006) Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 80 : 710–722. 16378974

20. Compton T, Nepomuceno RR, Nowlin DM (1992) Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface. Virology 191 : 387–395. 1329327

21. Li L, Nelson JA, Britt WJ (1997) Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol 71 : 3090–3097. 9060671

22. Huber MT, Compton T (1998) The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol 72 : 8191–8197. 9733861

23. Vanarsdall AL, Chase MC, Johnson DC (2011) Human cytomegalovirus glycoprotein gO complexes with gH/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells. J Virol 85 : 11638–11645. doi: 10.1128/JVI.05659-11 21880752

24. Zhou M, Yu Q, Wechsler A, Ryckman BJ (2013) Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope. J Virol 87 : 9680–9690. doi: 10.1128/JVI.01167-13 23804643

25. Sinzger C, Schmidt K, Knapp J, Kahl M, Beck R, et al. (1999) Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol 80 (Pt 11): 2867–2877. 10580048

26. Jiang XJ, Adler B, Sampaio KL, Digel M, Jahn G, et al. (2008) UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions. J Virol 82 : 2802–2812. doi: 10.1128/JVI.01550-07 18184717

27. Ryckman BJ, Chase MC, Johnson DC (2008) HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc Natl Acad Sci U S A 105 : 14118–14123. doi: 10.1073/pnas.0804365105 18768787

28. Ciferri C, Chandramouli S, Donnarumma D, Nikitin PA, Cianfrocco MA, et al. (2015) Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. Proc Natl Acad Sci U S A.

29. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, et al. (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84 : 1005–1013. doi: 10.1128/JVI.01809-09 19889756

30. Freed DC, Tang Q, Tang A, Li F, He X, et al. (2013) Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A 110: E4997–5005. doi: 10.1073/pnas.1316517110 24297878

31. Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G, et al. (2014) Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A 111 : 17965–17970. doi: 10.1073/pnas.1415310111 25453106

32. Wussow F, Yue Y, Martinez J, Deere JD, Longmate J, et al. (2013) A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 87 : 1322–1332. doi: 10.1128/JVI.01669-12 23152525

33. Wen Y, Monroe J, Linton C, Archer J, Beard CW, et al. (2014) Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 32 : 3796–3804. doi: 10.1016/j.vaccine.2014.05.004 24837507

34. Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10: e1004524. doi: 10.1371/journal.ppat.1004524 25412505

35. Gerna G, Lilleri D, Callegaro A, Goglio A, Cortese S, et al. (2008) Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Transplantation 86 : 163–166. doi: 10.1097/TP.0b013e31817889e4 18622294

36. Nokta M, Tolpin MD, Nadler PI, Pollard RB (1994) Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet -⁠ and ganciclovir-induced inhibition of CMV replication. Antiviral Res 24 : 17–26. 7944310

37. Manley K, Anderson J, Yang F, Szustakowski J, Oakeley EJ, et al. (2011) Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10 : 197–209. doi: 10.1016/j.chom.2011.07.010 21925108

38. Fouts AE, Comps-Agrar L, Stengel KF, Ellerman D, Schoeffler AJ, et al. (2014) Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc Natl Acad Sci U S A 111 : 8209–8214. doi: 10.1073/pnas.1404653111 24843144

39. Radermacher M, Wagenknecht T, Verschoor A, Frank J (1987) Three-dimensional reconstruction from a single-exposure, random conical tilt series applied to the 50S ribosomal subunit of Escherichia coli. J Microsc 146 : 113–136. 3302267

40. Chowdary TK, Cairns TM, Atanasiu D, Cohen GH, Eisenberg RJ, et al. (2010) Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol 17 : 882–888. doi: 10.1038/nsmb.1837 20601960

41. Saccoccio FM, Sauer AL, Cui X, Armstrong AE, Habib el SE, et al. (2011) Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 29 : 2705–2711. doi: 10.1016/j.vaccine.2011.01.079 21310190

42. Cairns TM, Shaner MS, Zuo Y, Ponce-de-Leon M, Baribaud I, et al. (2006) Epitope mapping of herpes simplex virus type 2 gH/gL defines distinct antigenic sites, including some associated with biological function. J Virol 80 : 2596–2608. 16501070

43. Connolly SA, Jackson JO, Jardetzky TS, Longnecker R (2011) Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol 9 : 369–381. doi: 10.1038/nrmicro2548 21478902

44. Leitner A, Reischl R, Walzthoeni T, Herzog F, Bohn S, et al. (2012) Expanding the chemical cross-linking toolbox by the use of multiple proteases and enrichment by size exclusion chromatography. Mol Cell Proteomics 11: M111 014126. doi: 10.1074/mcp.M111.014126 22286754

45. Walzthoeni T, Claassen M, Leitner A, Herzog F, Bohn S, et al. (2012) False discovery rate estimation for cross-linked peptides identified by mass spectrometry. Nat Methods 9 : 901–903. doi: 10.1038/nmeth.2103 22772729

46. Tang G, Peng L, Baldwin PR, Mann DS, Jiang W, et al. (2007) EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol 157 : 38–46. 16859925

47. van Heel M, Harauz G, Orlova EV, Schmidt R, Schatz M (1996) A new generation of the IMAGIC image processing system. J Struct Biol 116 : 17–24. 8742718

48. Scheres SH, Nunez-Ramirez R, Sorzano CO, Carazo JM, Marabini R (2008) Image processing for electron microscopy single-particle analysis using XMIPP. Nat Protoc 3 : 977–990. doi: 10.1038/nprot.2008.62 18536645